NVCR

Health Care Sector Update for 11/28/2023: NVCR, RNA, EBS

Health care stocks fell Tuesday afternoon with the NYSE Health Care Index down 0.4% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.3%.

The iShares Biotechnology ETF (IBB) dropped 0.6%.

In corporate news, NovoCure (NVCR) shares rose 2.6% after the company said it aims to cut $60 million in residual operating expenses under a restructuring plan that includes reducing its workforce by 13%.

Avidity Biosciences (RNA) jumped 19%. The company is collaborating with Bristol-Myers Squibb (BMY) to discover, develop, and market up to five cardiovascular targets using the former's antibody oligonucleotide conjugates technology with potential payments of up to $2.3 billion.

Emergent Biosolutions (EBS) said Tuesday it was awarded a $75 million option by the US government for the procurement of the company's newly licensed Cyfendus anthrax vaccine. Its shares fell 3.9%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.